Investor Overview

2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.

Read More >

Latest News

Neovasc will Request Nasdaq Hearing after Company Received Expected Delisting Determination from Nasdaq Staff

> read full release

Archive >

Programs and Events

Neovasc Presentation - January 2020

.pdf format >

Live Webcast - Neovasc Presentation at the
SVB Leerink Global Healthcare Conference
Wed. February 26th, 3:00p.m. EST

Neovasc CEO Fred Colen will be the presenter.
A replay will be accessible after the live webcast.

register for webcast >

NEOVASC REDUCER IS NOW RECOGNIZED IN THE ESC GUIDELINES FOR THE TREATMENT OF REFRACTORY ANGINA

learn more >

Financial Report Archives

2019 Financial Reports

News Release Archives

2020 News Releases

Share Information

Auditor
Grant Thornton LLP, Vancouver, BC

Legal Counsel
Blakes LLP, Vancouver, BC

Transfer Agent
Computershare, Vancouver, BC

Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com

To automatically receive news updates

register now